Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?

MLA

Volk, Annabelle, et al. “Stromal PDGFR-Beta Expression Is a Prognostic Factor in High-Grade Serous Ovarian Cancer Patients but Is It Also Predictive for Response to Antiangiogenic Treatment?” Journal of Cancer Research & Clinical Oncology, vol. 151, no. 2, Feb. 2025, pp. 1–10. EBSCOhost, https://doi.org/10.1007/s00432-025-06090-4.

APA

Volk, A., von Bülow, C., Stern, A., Simon, R., Burandt, E., Sauter, G., Schmalfeldt, B., & Oliveira-Ferrer, L. (2025). Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment? Journal of Cancer Research & Clinical Oncology, 151(2), 1–10. https://doi.org/10.1007/s00432-025-06090-4

Chicago

Volk, Annabelle, Charlotte von Bülow, Aysche Stern, Ronald Simon, Eike Burandt, Guido Sauter, Barbara Schmalfeldt, and Leticia Oliveira-Ferrer. 2025. “Stromal PDGFR-Beta Expression Is a Prognostic Factor in High-Grade Serous Ovarian Cancer Patients but Is It Also Predictive for Response to Antiangiogenic Treatment?” Journal of Cancer Research & Clinical Oncology 151 (2): 1–10. doi:10.1007/s00432-025-06090-4.